Combining NT3-overexpressing MSCs and PLGA microcarriers for brain tissue engineering: A potential tool for treatment of Parkinson's disease

Moradian, Hanieh; Keshvari, Hamid; Fasehee, Hamidreza; Dinarvand, Rassoul; Faghihi, Shahab

doi:10.1016/j.msec.2017.02.178

Cited by 38 publications

(17 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another gene responsible for CNS tissues protection is neurotrophin-3 (nt-3gene) which enhances neuronal-like differentiation. Overexpression of this gene in MSCs promotes the expression of tyrosine hydroxylase (TH), an indicator of the intracellular signaling in dopaminergic neuron differentiation (169).…”

Section: Parkinson's Diseasementioning

confidence: 99%

Manipulated Mesenchymal Stem Cells Applications in Neurodegenerative Diseases

Sadatpoor

Salehi

Rahban

et al. 2020

IJSC

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are multipotent stem cells that have multilinear differentiation and self-renewal abilities. These cells are immune-privileged as they express no or low level of class-II major histocompatibility complex (MHC-II) and other costimulatory molecules. Having neuroprotective and regenerative properties, MSCs can be used to ameliorate several intractable neurodegenerative disorders by affecting both innate and adaptive immune systems. Several manipulations like pretreating MSCs with different conditions or agents, and using molecules derived from MSCs or genetically manipulating them, are the common and practical ways that can be used to strengthen MSCs survival and potency. Improved MSCs can have significantly enhanced impacts on diseases compared to MSCs not manipulated. In this review, we describe some of the most important manipulations that have been exerted on MSCs to improve their therapeutic functions and their applications in ameliorating three prevalent neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

show abstract

Section: Parkinson's Diseasementioning

confidence: 99%

Manipulated Mesenchymal Stem Cells Applications in Neurodegenerative Diseases

Sadatpoor

Salehi

Rahban

et al. 2020

IJSC

View full text Add to dashboard Cite

show abstract

“…The signs and symptoms of PD are mild initially and may occasionally be overlooked. 63 In 2015, PD influenced 6.2 million people and about 117,400 deaths globally have been occurred. PD typically occurs in human older than 60 years, or 1% of human population.…”

Section: Neural Tissue Engineeringmentioning

confidence: 99%

“…In the PD treatment, bone marrowderived mesenchymal stem cells (BMSCs) were genetically designed to overcome the neurotrophin-3 (nt-3) gene that inhibits central nervous system and activated like neuronal differentiation of BMSCs. 63 PLGA microcarriers were modified as a proper tissue and prepared by double emulsion method. The surface of PLGA microcarriers was modified by collagen as a bioadhesive factor for enhanced cell attachment.…”

Section: Neural Tissue Engineeringmentioning

confidence: 99%

A review of using green chemistry methods for biomaterials in tissue engineering

Jahangirian¹,

Lemraski²,

Rafiee-Moghaddam³

et al. 2018

IJN

View full text Add to dashboard Cite

Although environmentally safe, or green, technologies have revolutionized other fields (such as consumables, automobiles, etc.), its use in biomaterials is still at its infancy. However, in the few cases in which safe manufacturing technology and materials have been implemented to prevent postpollution and reduce the consumption of synthesized scaffold (such as bone, cartilage, blood cell, nerve, skin, and muscle) has had a significant impact on different applications of tissue engineering. In the present research, we report the use of biological materials as templates for preparing different kinds of tissues and the application of safe green methods in tissue engineering technology. These include green methods for bone and tissue engineering-based biomaterials, which have received the greatest amount of citations in recent years. Thoughts on what is needed for this field to grow are also critically included. In this paper, the impending applications of safe, ecofriendly materials and green methods in tissue engineering have been detailed.

show abstract

“…21,22 Bone marrow-derived stem cells (BMSCs) improve nerve repair in the peripheral nervous system 23 and the central nervous system 24 in some animal lesion models. In previous studies, allogeneic BMSCs were mostly used, 25,26 but allogeneic BMSCs still have the potential to cause inflammatory reactions. In this study, to rule out this interference factor, we used autologous BMSCs for the transplantation to avoid concealing a negative effect of XANs in the process of nerve regeneration.…”

Section: Introductionmentioning

confidence: 99%

Xenogeneic acellular nerve scaffolds supplemented with autologous bone marrow‐derived stem cells promote axonal outgrowth and remyelination but not nerve function

Hou

Cai

Chen

et al. 2018

J Biomedical Materials Res

View full text Add to dashboard Cite

Autologous nerves, artificial scaffolds or acellular nerve scaffolds are commonly used in bridging treatment for peripheral nerve defects. Xenogeneic acellular nerve scaffolds and allogeneic cellular nerve scaffolds have the same structural characteristics. Due to the wider source of raw materials, these latter scaffolds have high-potential value for applications. However, whether their heterogeneity will affect nerve regeneration is unknown. The current study evaluated the efficiency of xenogeneic acellular nerve scaffolds (XANs) combined with 5-ethynyl-2'-deoxyuridine (EdU)-labeling of autologous bone marrow-derived stem cells (BMSCs) for repair of a 1.5 cm gap in rat sciatic nerves. XANs from rabbit tibial nerves were prepared, the structure and components of the scaffolds were evaluated after completely removing the cellular components. Animals were divided into four groups based on graft: the simple XAN group, the XAN + BMSC group, the XAN + Media (from BMSC culture) group, and the autograft group. Serological immune tests showed that XANs induce an immune response in the first 2 weeks after transplantation. Moreover, cell tracking revealed that the proportion of EdU+ cells decreased over time, as shown by the measures at 2 days (70%), 4 days (20%), and 8 days (even <3%) postoperatively. Nerve functional analyses revealed that in contrast to the autograft group results, the XAN-BMSC, XAN + Media, and XAN groups did not exhibit good restoration of the sciatic functional index (SFI) or electrophysiological results (the peak action potential amplitudes) 12 weeks, postoperatively. However, the XAN-BMSC and autograft groups demonstrated greater remyelination and increased axon numbers and myelin thickness than the XAN + Media and XAN groups 12 weeks, postoperatively (p < .05). In conclusion, in the early stage of transplantation, XANs induce a certain degree of inflammation. Although the combination of XANs with autologous BMSCs enhanced the number of regenerated axons and the remyelination, the combination did not effectively improve the recovery of nervous motor function. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 3065-3078, 2018.

show abstract

Combining NT3-overexpressing MSCs and PLGA microcarriers for brain tissue engineering: A potential tool for treatment of Parkinson's disease

Cited by 38 publications

References 53 publications

Manipulated Mesenchymal Stem Cells Applications in Neurodegenerative Diseases

Manipulated Mesenchymal Stem Cells Applications in Neurodegenerative Diseases

A review of using green chemistry methods for biomaterials in tissue engineering

Xenogeneic acellular nerve scaffolds supplemented with autologous bone marrow‐derived stem cells promote axonal outgrowth and remyelination but not nerve function

Contact Info

Product

Resources

About